key: cord-0883605-kfktsqeq
authors: Bucciol, Giorgia; Tangye, Stuart G.; Meyts, Isabelle
title: Coronavirus disease 2019 in patients with inborn errors of immunity: lessons learned
date: 2021-09-22
journal: Curr Opin Pediatr
DOI: 10.1097/mop.0000000000001062
sha: 416bfb06525eeca81600f77283e0c8f77760522f
doc_id: 883605
cord_uid: kfktsqeq

PURPOSE OF REVIEW: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic has caused extreme concern for patients with inborn errors of immunity (IEIs). In the first 6 months of the pandemic, the case fatality rate among patients with IEIs resembled that of the general population (9%). This review aims at summarizing what we have learned about the course and outcome of coronavirus disease 2019 (COVID-19) in patients with different IEIs and what this can potentially teach us about the immune mechanisms that could confer protection or predisposition to severe disease. RECENT FINDINGS: A total of 649 patients with IEI and COVID-19 have been reported in the last year and a half, spanning all groups of the International Union of Immunological Societies classification of IEIs. For most patients, the underlying IEI does not represent an independent risk factor for severe COVID-19. In fact, some IEI may even be protective against the severe disease due to impaired inflammation resulting in less immune-mediated collateral tissue damage. SUMMARY: We review the characteristics of SARS-CoV-2 infection in a large number of patients with IEI. Overall, we found that combined immunodeficiencies, immune dysregulation disorders, and innate immune defects impairing type I interferon responses are associated with severe disease course.

More than a year and a half into the coronavirus disease 2019 (COVID-19) pandemic, the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has infected more than 200 million individuals (confirmed cases) and caused more than 4 million deaths. Despite shielding and being prioritized in vaccination campaigns in many countries, many patients with previously known inborn errors of immunity (IEIs) became infected with SARS-CoV-2 and hundreds of these cases have now been reported in the scientific literature. Moreover, a number of reports validated the hypothesis that individuals who became severely ill with SARS-CoV-2 -a primary infection for both children and adults -could suffer from a hitherto unknown defined error of immunity . Based on these studies, a picture of the impact of COVID-19 in IEI is emerging. Furthermore, we are quickly understanding the fundamental requirements for successful host defense against SARS-CoV-2, as well as immune mechanisms that contribute to disease severity.

SARS-CoV-2, spanning all subgroups of immune defects as defined by the International Union of Immunological Societies committee for IEI (Table 1) Patients were mostly included based on a positive molecular test, antigenic test, or serology, although some reports also include patients with symptoms and clinical imaging compatible with a diagnosis of COVID-19, with or without a history of exposure to infected individuals [10, 12, 14, 15, 18] . As a result, the case fatality rate (CFR) attributed to COVID-19 could be overestimated in some reports. For example, in a UK cohort of 67 patients with IEI Shields et al. [15] report 12 patients as having succumbed to COVID-19, although only 47 (62.7%) had a PCRproven or serology-proven infection. Counting the remaining 20 patients as COVID-19 cases without proof could have led to an overestimation of COVID-19-related morbidity and mortality. Of note, since our knowledge on the multiple facets and complications COVID-19, such as multisystem inflammatory syndrome in children (MIS-C) and in adults (MIS-A), has grown gradually during the pandemic, some relevant features of the disease were not highlighted in early reports [5 & ].

Reflecting the relative frequency of humoral immunodeficiencies among IEIs, the majority of patients who experienced COVID-19 are affected by antibody deficiency (n ¼ 330, 51%) [5 & ,9 & ,10, [12] [13] [14] [15] [16] [17] 19, 24, 26, 28, 30, 33, 34, 36, 37, 42, 44, 45, 48, 52, 53, [57] [58] [59] [60] [61] [62] 64, [66] [67] [68] [69] . Among them, 200 have common variable immunodeficiency (CVID, 60% of all antibody deficiencies), 59 have X-linked agammaglobulinemia (XLA, 18%) and eight have autosomal recessive agammaglobulinemia (2%). The remaining 63 patients have other B-cell defects including TRNT1 deficiency (n ¼ 1), activated PI3Kd syndrome (APDS, n ¼ 4), IgG subclass deficiency (n ¼ 2), specific polysaccharide antibody deficiency (SPAD, n ¼ 13), isolated IgA deficiency (n ¼ 15), or unspecified antibody deficiency (n ¼ 28). The rate of admission to ICU is 14% for the whole group of patients with Ab deficiencies and the subgroups of CVID and XLA patients. CFR is 8% for the whole group (n ¼ 26), 9% for CVID, 8% for XLA, 8% for SPAD, and 13% for the unspecified antibody deficiencies, while the CFR of patients with IgA deficiency, other

IEIs in general do not represent an independent risk factor for severe SARS-CoV-2 infection.

Combined immunodeficiencies, immune dysregulation disorders and defects of innate immunity impairing type I interferon responses, show a higher rate of severe disease and higher mortality.

Inborn errors of type I interferon responses and IEI in which patients harbor autoantibodies against these cytokines, confer a high risk for critical COVID-19, reflecting the crucial role of type I interferon in host defense against SARS-CoV-2. [12] [13] [14] 39, 49, 51] . The CFR among children with SCID who had not been treated with HSCT is strikingly high (n ¼ 4/7, all affected by preexisting unspecified lower respiratory tract infections, and one with Omenn syndrome also by BCGitis [13] ), while none of the SCID patients after curative treatment required admission to the ICU or died, even in case of progressive graft failure (n ¼ 1) [5 & ,10, 12, 14, 39, 49, 51] . The cause of death was respiratory failure in all four cases [13] . In addition, an adult with unspecified CID died of HLH, an adolescent with CD40L deficiency died of MIS-C with pneumonia, and a child with serine-threonine protein kinase 4 deficiency had hepatitis, bloody diarrhea, and died of cardiorespiratory failure [10, 13, 16] . Among syndromic forms of CID, SARS-CoV-2 infection has been reported in six patients ( 16, 27, 43] . Of three Wiskott-Aldrich syndrome (WAS) patients who underwent HSCT (n ¼ 2) or gene therapy (n ¼ 1), one succumbed to cytomegalovirus (CMV) encephalitis and bacterial pneumonia, while the other two survived [5 & ,10]. Two patients who were transplanted to treat X-linked proliferative syndrome due to mutations in the gene encoding X-linked inhibitor of apoptosis protein (XIAP) died after being infected with SARS-CoV-2 post-HSCT: one was infected on day 6 post-HSCT and had a mild disease, but later succumbed to fungal infection in the context of poor engraftment, and the other died of sepsis and HLH in the context of severe graft-versus-host disease (GVHD) [5 & ,10]. One patient each was transplanted for leukocyte adhesion deficiency III, nuclear factor-kappa B (NF-kB) essential modulator (NEMO) deficiency, cytotoxic T-lymphocyte associated protein 4 (CTLA4) haploinsufficiency, Chediak-Higashi syndrome, or chronic granulomatous disease (CGD), and all survived COVID- 19 

As for immune dysregulation disorders, COVID-19 has been reported in 62 patients (10%), the majority of whom were affected by autoimmune polyendocrine syndrome type 1 (APS-1, 13, 14, 16, 21, 22, 37, 40, 56, 57, 70] . The rate of ICU admission was 28% and CFR 15% (n ¼ 9). The rate of admission to the ICU rises to 41% for APS-1 patients, while CFR remains at 15% (n ¼ 4). All APS-1 patients who died succumbed to respiratory failure [21] . The high rate of severe disease and mortality among APS-1 patients is explained by their preexisting neutralizing antitype I interferon autoantibodies (anti-IFN-a and/or v), which were shown to block the initial antiviral type I interferon response by Bastard et al. 

Autoinflammatory disorders were present in 54 12, 13, 20] . The rate of ICU admission was 4% and CFR 6% (n ¼ 3) for the entire group, while both ICU admission rate and CFR were 3% (n ¼ 1) for FMF patients. One child with unspecified autoinflammatory disease died of MIS-C and vasculitis, while a child with deficiency of IL-1 receptor antagonist syndrome died of respiratory failure [12, 13] ¼ 4) . In one case, cause of death was septic shock and in another one neurological involvement with seizures, cerebral sinus thrombosis and venous infarction, and multiorgan failure [23, 47] .

Thirty-four patients with phagocyte defects are reported (5%), among whom 18 

Twenty-nine patients with complement deficiency, mostly hereditary angioedema, had mild or asymptomatic COVID-19 (4%) [10, 15] . In some cases, infection was associated with an angioedema attack, however no infected patients required ICU admission, and all patients recovered.

Finally, seven patients with Good syndrome (thymoma with hypogammaglobulinemia, 1%) have been reported to have been infected with SARS-CoV-2 [9 & ,10,12,32,42]. They mostly displayed a severe phenotype, with 5/7 (75%) patients requiring admission to ICU admission, and three patients succumbing (CFR 43%). Cause of death in one case was respiratory failure, and septic shock, myocarditis, pneumonia and hyperinflammation in another [10, 12] .

When the first reports on COVID-19 in patients with IEI emerged in 2020, we learned that overall mortality among these patients was comparable with global mortality at the time and that patients shared the same risk factors for severe and critical disease as the general population, though the median age of IEI patients with severe COVID-19 was lower and the rate of admission to ICU per age group higher [5 patients), which is higher than in the general population [global average 2.1% (range: 0.5-18%), <0.3% <40 years to 13-20% >80 years] [72] [73] [74] [75] . Among the IEI patients reported with their age, CFR is 10% among children, 7% for 20-40 years, 10% for 40-60 years, 14% for 60-70 years, and 36% for >70 years. Among the 18 children with IEI who died, eight (47%) had a CID, three (17%) had an immune dysregulation disorder, two each (12%) an autoinflammatory disease, a phagocyte defect or XLA, and one an innate immunity disorder [5 & ,10, 12, 13, 47] . This includes four children with SCID pre-HSCT and five patients who either died from causes not directly related to COVID-19, or who were already in a severely compromised state at the time of infection. Mortality in the group aged 20-40 years was dominated by patients with APS-1 (4/9, 44%), followed by XLA and innate immunity disorders (two each, 22%), and CID (1/9, 11%). Above 40 years of age, 75% of deaths occurred among antibody deficient patients.

Differences between the CFRs in the IEI group and the general population can be explained by two factors: on the one hand, large scale screening for SARS-CoV-2 infection has significantly lowered the CFR in the general population. On the other hand, patients with IEIs tend to have more comorbidities at a younger age than the average otherwise-healthy person. Moreover, physicians tend to publish single cases when they are remarkable in their course or outcome, thus introducing a bias toward more severe cases being reported. Indeed, a large and elegant unbiased cohort study conducted by Milito et al. ] on the whole Italian population of IEI patients with confirmed SARS-CoV-2 infection revealed a CFR of 3.8% in IEIs, which is very close to the overall CFR in Italy ($3%).

The CFR of COVID-19 in CIDs is slightly higher than the average for all IEIs reported to date (13%). Mortality from SARS-CoV-2 is extremely high in children with SCID pretransplantation, while SCID patients who underwent curative procedures show 100% survival rate, with no severe cases reported [10, [12] [13] [14] 39, 49] . Together with fatal COVID-19 in three patients with acute and severe complications post-HSCT (GVHD, CMV infection, fungal infection, and graft failure), this could either indicate a role of cellular immunity in controlling SARS-CoV-2 infection, or an increased mortality in the context of an already compromised general state. ]. These findings were confirmed by several groups [21, 22, [76] [77] [78] [79] [80] [81] . For APS-1 patients, the presence of antitype I interferon antibodies was well known; however, no viral infection phenotype had been described until the pandemic [82] . Despite this, CFR among APS-1 patients is like the whole group of immune dysregulation disorders, indicating that immune dysregulation diseases arising from distinct genetic causes can predispose to severe COVID-19. On the other hand, patients affected by autoinflammatory disorders do not seem to have a specifically higher risk of severe COVID-19 and have mostly a mild course [5 & ,10,20]. One prediction would be that elevated production or action of type I interferon, as one of the inflammatory mechanisms, provides effective innate host defense against SARS-CoV-2 infection, thereby minimizing disease severity. have recently identified an additional 14 deleterious TLR7 alleles in males with critical COVID-19. They showed an impaired type I interferon production by plasmacytoid dendritic cells. Significantly, several cases of very severe SARS-CoV-2 pneumonia in patients with MyD88 deficiency have also been reported [71] . This is arguably surprising since individuals with MyD88-deficiency have previously only been reported to suffer from severe invasive bacterial infections, rather than any viruses [83] . A previous study on SARS-CoV-1 demonstrated that MyD88 has an essential role in mice in controlling pulmonary viral replication [84] . Thus, it is possible that MyD88 plays a hitherto unknown role in early antiviral response against coronaviruses.

A new COVID-19-related clinical entity affecting children emerged in the first few months of the pandemic, namely MIS-C [85,86,87,88 & ]. Unlike in acute COVID-19-related hyperinflammation, where multisystem inflammation and cytokine storm go together with severe respiratory symptoms and typically affect adults, MIS-C appears several weeks after SARS-CoV-2 exposure and is not correlated with the severity of the initial infection [85,86,87,88 & ]. Similarly, MIS-A has been reported in adults [89] . Patients with MIS-C and MIS-A present with multiorgan involvement without severe respiratory illness, preceded by 4-6 weeks by an asymptomatic or paucisymptomatic SARS-CoV-2 infection. SARS-CoV-2 antibodies, positive PCR or a history of exposure are detected in almost all cases [85] [86] [87] 89] . Although partly overlapping with Kawasaki disease, MIS-C generally affects older children (7.5-12 years), with a predilection for males and subjects of African or Hispanic ancestry. In more than 70% of cases patients have multiorgan dysfunction with mucocutaneous (70%), gastrointestinal (>80%), cardiovascular (80-100%), respiratory (50-70%), or neurologic involvement (40%) [85,86,87,88 & ,90] . It has a more severe clinical course, often presenting with shock (50%), and a high prevalence of myocarditis (90%) [85,86,87,88 & ]. Finally, it is associated with a pronounced hyperinflammatory state with higher levels of inflammatory markers and more severe cytopenia than in Kawasaki disease, often fulfilling the diagnostic criteria for HLH [85,86,87,88 & ]. Among the 649 IEI patients with COVID-19, at least 23 had MIS-C or HLH. Ten patients (six children, four adults) met the criteria for HLH, although it is possible some of them would have been diagnosed with MIS-C if this entity had been known at the time of the earliest presentations [5 & ]. Seven out of ten of these patients also had pneumonia or acute respiratory distress syndrome (ARDS), eight required ICU admission and three died (one adult, two children). Fourteen children (two females) were classified as suffering from MIS-C (median age 11 years, range 1-17) [3,4,5 & ,12]. Seven out of 14 also had pneumonia or ARDS, six were admitted to the ICU and three died. There were no reports of MIS-A among patients with IEI, although hyperinflammation in the context of SARS-CoV-2 pneumonia was described [5 & ,12] . Notably, there is an overrepresentation of disorders of immune dysregulation (5/62 patients, 8%, including two XIAP deficiency, one Chediak-Higashi syndrome and one SOCS1 deficiency) and phagocyte defects (4/34 patients, 11%, including three CGD), which are associated to increased or chronic inflammation.

The description of the clinical course and outcome of hundreds of patients with an IEI infected with SARS-CoV-2 since the beginning of the pandemic gives us a better understanding of predisposing factors and immunological mechanisms underlying severe COVID-19. First, the crucial role of the type I interferon response is convincingly shown by the enrichment in pathogenic variant in genes responsible for interferon production and downstream signaling in several patients with critical 23] . Similarly, a high rate of severe disease occurred in patients with preexisting antitype I interferon autoantibodies, such as patients with APS-1 [21] . In fact, autosomal inborn errors of type I immunity and antitype I interferon autoantibodies underlie at least 10% of critical COVID-19 cases. A hypothesis that needs to be further explored is that the higher CFR and ICU admission rates seen in patients with different types of IEIs, and patients with disorders of immune dysregulation in particular, could be caused by the presence of these autoantibodies. Autoimmunity is indeed a feature of many IEIs and phenocopies of IEIs, like Good syndrome, in which antitype I interferon autoantibodies have already been described [91] [92] [93] [94] . A collaborative effort to screen patients with IEI for anti-interferon auto-antibodies is ongoing (www.covidhge.com) [95] [96] [97] .

The initial observation that patients with XLA had better outcomes than patients with CVID, possibly due to the absence of the proinflammatory Bruton tyrosin kinase (BTK)-dependent NF-kB activation, is not reflected in this larger cohort of patients, who show the same ICU admission rates and a similar CFR (9 vs. 8% in CVID and XLA patients, respectively) [5 & ,11]. Since the median age of CVID patients is 40 years and that of patients with XLA or agammaglobulinemia is 23 years, patients with XLA seem to have a worse outcome at a younger age. This could potentially be explained by the fact that CVID patients often present later in life and so develop comorbidities at a later age, while patients with agammaglobulinemia often have chronic lung damage already in childhood. Alternatively CVID patients could have antitype I interferon autoantibodies as part of an autoimmune phenotype. Although patients with disorders of immune dysregulation are more at risk for both severe pulmonary COVID-19 and its inflammatory complications, such as MIS-C or HLH, patients with phagocyte defects are not susceptible to SARS-CoV-2 pneumonia but have an increased risk of hyperinflammation [4,5 & ,12] . Significantly, patients with autoinflammatory disorders such as FMF and AGS also show no increased risk of severe disease compared with the general population [5 & ,10,20].

Insight into immune mechanisms responsible for SARS-CoV-2 immunity and inflammation is driving therapeuticl trials with IL-6 inhibition with tocilizumab, BTK inhibition with ibrutinib and acalabrutinib, or JAK-STAT inhibition with ruxolitinib in patients with severe hyperinflammation in the context of COVID-19 [98,99,100 & ]. Early therapy with type I interferon has also been attempted in several patients, although the timing of this treatment is challenging [100 & ,101,102] . Caution should be used with regard to convalescent plasma, which has been successfully administered to several patients with IEIs and prolonged COVID-19, but has also been found to harbor antitype I interferon autoantibodies [27, 33, 39, 42, 45, 48, 49, 76] . Therapeutic plasma exchange could be beneficial to remove deleterious autoantibodies and proinflammatory cytokines in critical patients, and it has been attempted with anecdotal positive results [100 & , [103] [104] [105] . Monoclonal antibodies that neutralize SARS-CoV-2, such as the combination of casirivimab and imdevimab (Regen-Cov) or sotrovimab, have also proven effective as primary or secondary prevention of COVID-19 [106, 107] . Therefore, passive immunotherapy with these antibodies could potentially be used early in patients with IEIs at high risk for severe disease as a strategy to prevent the development of COVID-19-related complications or as aids in clearing the infection in patients with prolonged shedding of SARS-CoV-2 [108] . Finally, some patients with IEI are able to mount a humoral and/ or cellular immunity against the virus in a natural infection setting or in a vaccination setting [67, 109, 110] . RNA-based vaccines against SARS-CoV-2 have proven safe and effective in patients with IEI, who should therefore be prioritized for early vaccination around the world, together with their family members as a mean of communitybased protection in case of insufficient individual response to the vaccine [109, 111] .

We reviewed the characteristics and outcome of SARS-CoV-2 infection in patients with IEI and found that the underlying immune defect does not represent an independent risk factor for severe COVID-19, except for CID -though the number of patients is small-but especially immune dysregulation disorders (APS-1) and innate immune defects impairing type I interferon responses. Further studies are needed to assess the role of anti-type I interferon antibodies in larger cohorts of individuals with IEI and critical COVID-19, to better direct the therapeutic strategies most apt to prevent or treat severe complications in these patients.

We want to thank Yoni Maisel, whose Twitter updates on SARS-CoV-2 in patients with PID were extremely helpful for this work. We also want to thank the COVID19-Human Genetic Effort consortium and its leaders Prof Jean-Laurent Casanova and Prof Helen Su for the insightful discussions and collaborative scientific project since the onset of the pandemic. 9.

The article uses an elegant and unbiased approach to analyze the impact of COVID-19 in the Italian cohort of patients with IEIs, showing rates of severe disease and mortality similar to the general Italian population

A possible role for B cells in COVID-19? Lesson from patients with agammaglobulinemia

COVID-19 in the context of inborn errors of immunity: a case series of 31 patients from Mexico

Impact of SARS-CoV-2 pandemic on patients with primary immunodeficiency

Minor clinical impact of COVID-19 pandemic on patients with primary immunodeficiency in Israel

COVID-19 in patients with primary and secondary immunodeficiency: the United Kingdom experience

COVID-19 in patients with primary immunodeficiency

Characteristics of COVID-19 infection and antibody formation in patients known at a tertiary immunology department

COVID-19 affecting hereditary angioedema patients with and without C1 inhibitor deficiency

COVID-19 infection in 10 common variable immunodeficiency patients in New York City

COVID-19 outcomes in patients with familial Mediterranean fever: a retrospective cohort study

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1

Mild COVID-19 despite autoantibodies to type I IFNs in Autoimmune-Polyendocrine-Syndrome Type 1 (APS-1)

Presence of genetic variants among young men with severe COVID-19

COVID-19 in a child with primary antibody deficiency

Severe SARS-CoV-2 disease in the context of a NF-kB2 loss-of-function pathogenic variant

Positive outcome in a patient with coronavirus disease 2019 and common variable immunodeficiency after intravenous immunoglobulin

Management of COVID-19 pneumonia in a child with NEMO deficiency

The clinical course of COVID-19 pneumonia in a 19-year-old man on intravenous immunoglobulin replacement therapy for X-linked agammaglobulinemia

A COVID-19 pneumonia case report of autoimmune polyendocrine syndrome type 1 in Lombardy Italy: letter to the

Treatment of COVID-19 with remdesivir in the absence of humoral immunity: a case report

A male infant with COVID-19 in the context of ARPC1B deficiency

Severe COVID-19 pneumonia in Good syndrome with a favorable outcome

Treatment of COVID-19 with convalescent plasma in patients with humoral immunodeficiency -Three consecutive cases and review of the literature

The clinical observation of a patient with common variable immunodeficiency diagnosed as having coronavirus disease

SARS-CoV-2 infection in a pediatrics STAT1 GOF patient under Ruxolitinib therapy-a matter of balance?

SARS-CoV-2-associated T-cell responses in the presence of humoral immunodeficiency

Clinical outcomes and features of COVID-19 in patients with primary immunodeficiencies in New York City

IFN-g receptor 2 deficiency initial mimicry of multisystem inflammatory syndrome in children (MIS-C)

Case report: convalescent plasma achieves SARS-CoV-2 viral clearance in a patient with persistently high viral replication over 8 weeks due to severe combined immunodeficiency (SCID) and graft failure

Primary haemophagocytic lymphohistiocytosis (Ché diak-Higashi syndrome) triggered by acute SARS-CoV-2 infection in a 6-week-old infant

Severe COVID-19 in an APS1 patient with interferon autoantibodies treated with plasmapheresis

Severe COVID-19 in patients with B cell alymphocytosis and response to convalescent plasma therapy

Recovery from COVID-19 in a child with chronic granulomatous disease and T cell lymphopenia

Rapid recovery of a SARS-CoV-2-infected X-linked agammaglobulinemia patient after infusion of COVID-19 convalescent plasma

A fatal case of coronavirus disease 2019 in a patient with common variable immunodeficiency

Fatal SARS-CoV-2 infection in a male patient with Good's syndrome

TBK1 and TNFRSF13B mutations and an autoinflammatory disease in a child with lethal COVID-19

Case report: convalescent plasma, a targeted therapy for patients with CVID and severe COVID-19

SARS-CoV-2 infection associated with hepatitis in an infant with X-linked severe combined immunodeficiency

An update on the use of immunomodulators in primary immunodeficiencies

COVID-19 after hematopoietic stem cell transplantation: report of two children

Recurrent pneumonia in a patient with new coronavirus infection after discharge from hospital for insufficient antibody production: a case report

COVID-19 in a patient with CVID and contraindications to several potential treatments

Self-limited COVID-19 in a patient with artemis hypomorphic SCID

Complications of coronavirus in a patient with CVID

COVID-19 in 3 patients with CLTA4 haploinsufficiency and absence of autoantibodies to type 1 interferons

The clinical coarse and outcome of SARS-COVID 19 in patients with inborn error of immunity, does it relate to the type of the immune defects

Treatment of COVID-19 with convalescent plasma in a patient with X-linked agammaglobulinemia

High dose intravenous immunoglobulin. The next step in therapy for severe COVID19 infection?

Positive SARS-CoV-2 RT-PCR testing in a pediatric patient with X-linked agammaglobulinemia

A patient with X-linked agammaglobulinemia and COVID-19 infection treated with remdesivir and convalescent plasma

Confirmed SARS-COV-2 infection in a cohort of children and young adults with moderate or severe primary immunodeficiencies

Clinical outcomes of SARS-CoV2 infection in STAT3 deficiency

Surprising protective mechanisms against severe forms of COVID-19 infection among common variable immunodeficiency patients-one center experience

Human inborn errors of immunity: 2019 update on the classification from the international union of immunological societies expert committee

COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study

Robust antibody and T cell responses to SARS-CoV-2 in patients with antibody deficiency

Possible COVID-19 reinfection in a patient with X-linked agammaglobulinaemia

Atypical course of COVID-19 in patient with Bruton agammaglobulinemia

COVID-19 presenting with autoimmune hemolytic anemia in the setting of underlying immune dysregulation

Varying illness severity in patients with MyD88 deficiency infected with coronavirus SARS-CoV-2

An interactive web-based dashboard to track COVID-19 in real time

Severe outcomes among patients with coronavirus disease 2019 (COVID-19) -United States

Geneva: WHO; 2021

European Centre for Disease Prevention and Control: COVID-19 situation update worldwide, as of week 31

Neutralizing autoantibodies to type I interferons in COVID-19 convalescent donor plasma

Autoantibodies against type I interferons are associated with multiorgan failure in COVID-19 patients

Neutralizing autoantibodies to type I IFNs in >10% of patients with severe COVID-19 pneumonia hospitalized in Madrid, Spain

Longitudinal single-cell epitope and RNA-sequencing reveals the immunological impact of type 1 interferon autoantibodies in critical COVID-19

Antibodies against type-I Interferon: detection and association with severe clinical outcome in COVID-19 patients

Early nasal type I IFN immunity against SARS-CoV-2 is compromised in patients with autoantibodies against type I IFNs

Anti-interferon autoantibodies in autoimmune polyendocrinopathy syndrome type 1

Clinical features and outcome of patients with IRAK-4 and MyD88 deficiency

MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV

An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study

Mapping systemic inflammation and antibody responses in multisystem inflammatory syndrome in children (MIS-C)

Distinctive features of Kawasaki disease following SARS-CoV-2 infection: a controlled study

The article analyses the characteristics of multisystem inflammatory syndrome in children

Case series of multisystem inflammatory syndrome in adults associated with SARS-CoV-2 infection -United Kingdom and United States March-August

Multisystem inflammatory syndrome in U.S. children and adolescents

Good syndrome, bad problem

Spontaneous neutralising antibodies to interferon-a and interleukin-12 in thymoma-associated autoimmune disease

Anticytokine autoantibodies in autoimmunity: preponderance of neutralizing autoantibodies against interferon-alpha, interferon-omega and interleukin-12 in patients with thymoma and/or myasthenia gravis

Anticytokine autoantibodies are associated with opportunistic infection in patients with thymic neoplasia

Broad-spectrum antibodies against self-antigens and cytokines in RAG deficiency

Unbalanced immune system: immunodeficiencies and autoimmunity

Good syndrome: an adult-onset immunodeficiency remarkable for its high incidence of invasive infections and autoimmune complications

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: a systematic review and meta-analysis of randomized controlled trials

Harnessing type I IFN immunity against SARS-CoV-2 with early administration of IFN-b

The article reviews the various therapies for COVID-19, focusing on those targeting the type I interferon responses and the proinflammatory pathways that are hyperactivated in severe disease

Interferon-b therapy in a patient with incontinentia pigmenti and autoantibodies against type I IFNs infected with SARS-CoV-2

IFN-a2a therapy in two patients with inborn errors of TLR3 and IRF3 infected with SARS-CoV-2

Plasma exchange in critically ill COVID-19 patients

Potential effect of blood purification therapy in reducing cytokine storm as a late complication of critically ill COVID-19

Plasma exchange to rescue patients with autoantibodies against type I interferons and life-threatening COVID-19 pneumonia

Subcutaneous REGEN-COV antibody combination to prevent Covid-19

SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19

Successful clearance of 300 day SARS-CoV-2 infection in a subject with B-cell depletion associated prolonged (B-DEAP) COVID by REGEN-COV anti-spike monoclonal antibody cocktail

Immunogenicity of Pfizer-BioNTech COVID-19 vaccine in patients with inborn errors of immunity

Seroconversion after coronavirus disease 2019 vaccination in patients with immune deficiency

Low seropositivity and sub-optimal neutralisation rates in patients fully vaccinated against COVID-19 with B cell malignancies